NAMS NewAmsterdam Pharma Corp: Price-to-Projected Revenue Ratio

NewAmsterdam Pharma - graphic logo of issuer NAMS

NewAmsterdam Pharma's success is based on clinical test results and regulatory approval of its cardiology products. The company's forward P/S trend confirms these expectations, with the current figure standing at 92.70. Growth is constrained by pressure from low-cost generics and the influence of industry behemoths, yet production stability is ensured through diversified raw material supply chains across various regions.

NewAmsterdam Pharma Company N.V. - NAMS Market Cap to Expected Sales Ratio (period 06/21/2023 - 11/16/2026)

Summary analytical data breakdowns for newamsterdampharma.com (NAMS)

- market price and analyst price targets:
Fundamental company valuation:newamsterdampharma.com NAMS
Original product of NewAmsterdam Pharma

Forward P/S is calculated as the ratio of current market capitalization to expected revenue for a future period, measuring the market premium for sales growth potential. Analyzing the historical forward P/S for NewAmsterdam Pharma (NAMS) allows for an assessment of the company's valuation fairness, considering its patents and expansion into the inelastic cholesterol medication market, where high coefficient stability confirms long-term margin sustainability.

Competitor analysis

Price-to-Projected Revenue Ratio ascendispharma.com ASND|Madrigal Corp (MDGL) - Market Cap to Future Revenue Ratio|CORT - Price-to-Projected Revenue Ratio|RYTM: Price-to-Projected Revenue Ratio|AKRO: Forward P/S Multiple|MTSR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MoonLake Corp|Crinetics Corp (CRNX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio soleno.life (SLNO)|Forward Price-to-Revenue Multiple Amicus Therapeutics FOLD|Forward Price to Sales 89bio Inc|Forward P/S Multiple Agios Pharmaceuticals, Inc. AGIO|GPCR: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio MiMedx Corp MDXG|RZLT (Rezolute Corp) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue LXRX|MBX (MBX Biosciences) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Altimmune Inc (ALT)|Forward Price-to-Revenue Multiple AARD (Aardvark Therapeutics Corp)|Forward Price-to-Revenue Multiple Sagimet SGMT|Forward P/S Multiple BIOA (BioAge Labs)|Forward P/S Multiple Biomea Fusion BMEA|QNCX: Forward Price-to-Revenue Multiple|GUTS: Price-to-Projected Revenue Ratio|vTv Therapeutics Inc (VTVT) - Price-to-Projected Revenue Ratio|ATPC: Price to Expected Revenue Ratio|PLUR (pluri-biotech.com) - Forward P/S Multiple|SYBX: Forward Price to Sales|Forward P/S Multiple LPCN|Market Cap to Expected Sales Ratio Matinas BioPharma Holdings, Inc.|Price-to-Projected Revenue Ratio Spruce Biosciences Inc. SPRB|GLTO - Forward Price-to-Revenue Multiple|CTCX - Price-to-Projected Revenue Ratio|LUMO - Forward P/S Multiple|ONVO: Forward P/S Multiple|RDUS (Radius Recycling) - Price-to-Projected Revenue Ratio